

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

RKO

RRID:CVCL_0504

Type: Cell Line

Proper Citation

RRID:CVCL_0504

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0504

Proper Citation: RRID:CVCL_0504

Description: Cell line RKO is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Colon carcinoma

Defining Citation: [PMID:2253215](#), [PMID:2835152](#), [PMID:6437669](#), [PMID:7329817](#), [PMID:7700629](#), [PMID:7761852](#), [PMID:7798274](#), [PMID:7824277](#), [PMID:8387205](#), [PMID:9515795](#), [PMID:9715273](#), [PMID:11314036](#), [PMID:12615714](#), [PMID:15161374](#), [PMID:16418264](#), [PMID:16854228](#), [PMID:17363507](#), [PMID:18258742](#), [PMID:20164919](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22278370](#), [PMID:22460905](#), [PMID:24042735](#), [PMID:24618588](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25841592](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:25984343](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28179481](#), [PMID:28192450](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:34320349](#), [PMID:35839778](#)

Comments: Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: KuDOS 95 cell line panel., Part of: ERK genetic alteration cell panel (ATCC TCP-1033)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RKO

Cross References: BTO:BTO_0001890, CLO:CLO_0008825, EFO:EFO_0001232, MCCL:MCC:0000401, AddexBio:C0009012/374, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2577, BioGRID_ORCS_Cell_line:477, BioSample:SAMN03471682, BioSample:SAMN03472274, BioSample:SAMN10988176, cancercellines:CVCL_0504, CCRID:1101HUM-PUMC000668, CCRID:3101HUMTCHu116, Cell_Model_Passport:SIDM01090, ChEMBL-Cells:ChEMBL3307731, ChEMBL-Targets:ChEMBL614879, CLS:305035, ColonAtlas:RKO, Cosmic:873164, Cosmic:887214, Cosmic:909698, Cosmic:948133, Cosmic:1043824, Cosmic:1131688, Cosmic:1132576, Cosmic:1132687, Cosmic:1154653, Cosmic:1184099, Cosmic:1184330, Cosmic:1187315, Cosmic:1223146, Cosmic:1303884, Cosmic:1310948, Cosmic:1312309, Cosmic:1479607, Cosmic:1537488, Cosmic:1552178, Cosmic:1676744, Cosmic:1708414, Cosmic:1805264, Cosmic:1888954, Cosmic:1995622, Cosmic:2302003, Cosmic:2550355, Cosmic:2588706, Cosmic:2646668, Cosmic:2650776, Cosmic:2667884, Cosmic:2667968, Cosmic:2668257, Cosmic:2727473, Cosmic:2787542, Cosmic:2811055, Cosmic-CLP:909698, DepMap:ACH-000943, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS740UAH, ENCODE:ENCBS954LTA, GDSC:909698, GEO:GSM206538, GEO:GSM274765, GEO:GSM274766, GEO:GSM383863, GEO:GSM741254, GEO:GSM844676, GEO:GSM887541, GEO:GSM888624, GEO:GSM1346884, GEO:GSM1374850, GEO:GSM1374851, GEO:GSM1374852, GEO:GSM1448132, GEO:GSM1670380, GEO:GSM2550011, KCB:KCB 2011102YJ, LiGeA:CCLE_267, LINCS_LDP:LCL-1168, Lonza:59, MetaboLights:MTBLS227, PharmacDB:RKO_1316_2019, PRIDE:PXD001550, PRIDE:PXD002395, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_0504, PubChem_Cell_line:CVCL_0504, TOKU-E:3013, Ubigen:YC-C002, Wikidata:Q54950538

ID: CVCL_0504

Record Creation Time: 20220427T221500+0000

Record Last Update: 20260905T182219+0000

Ratings and Alerts

No rating or validation information has been found for RKO.

No alerts have been found for RKO.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 159 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Huang C, et al. (2026) Pregnenolone promotes immune evasion through blocking endogenous retrovirus expression. *Cell metabolism*, 38(5), 981.

Brunner HL, et al. (2026) A multivalent adaptor mechanism drives the nuclear import of proteasomes. *Nature communications*, 17(1).

Duan X, et al. (2026) DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages. *Cancer immunology research*, 14(6), 900.

Pawar NR, et al. (2026) A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. *Molecular cancer therapeutics*.

Zhao L, et al. (2026) Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. *NPJ precision oncology*.

Liang J, et al. (2026) DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer. *Cell reports*, 45(8), 117719.

Zhou Z, et al. (2026) The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. *PLoS biology*, 24(1), e3003603.

Schwartz I, et al. (2026) Guardian ubiquitin E3 ligases target cancer-associated APOBEC3 deaminases for degradation to promote human genome integrity. *Nature communications*, 17(1), 1723.

Hollek V, et al. (2026) Pooled single-cell screen in colorectal cancer defines transcriptional modules linked to oncogenes. *Molecular systems biology*, 22(3), 435.

Renner F, et al. (2026) Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer. *Molecular cancer therapeutics*, 25(4), 599.

Nakajo S, et al. (2026) Hypoxic CAF studies unveil PTHrP?vitamin D?RAS axis as pivotal in the CAF. *Oncology reports*, 55(6).

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Huang Y, et al. (2026) Mechanosensation promotes broad-spectrum antiviral defense through membrane remodeling. *Cell chemical biology*, 33(3), 307.

Kwon YJ, et al. (2026) Basroparib inhibits YAP-driven cancers by stabilizing angiomin. *Molecular oncology*, 20(5), 1284.

De Boni L, et al. (2026) Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors. *iScience*, 29(3), 114954.

Liu J, et al. (2026) Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion. *Cell reports. Medicine*, 7(4), 102704.

Tong J, et al. (2026) p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. *Redox biology*, 90, 104043.

Fu D, et al. (2026) ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e16557.

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. *bioRxiv : the preprint server for biology*.

Kang Z, et al. (2026) LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. *Genome biology*, 27(1).